This is MATRIX time @ EuroPCR 2016.
I had the privilege of presenting one of the most important subsidies of the Matrix trial, PI Marco Valgimigli, assessing the role of transradial vs. transfemoral PCI either in STEMI or NSTE-ACS patients undergoing invasive management.
Results were consistent with the main publication in Lancet last year, showing a significant benefit in terms of NACE and a strong trend in terms of improvement of MACE for the transradial approach.
I am including the presentation as late-breaking clinical trial during EuroPCR 2016.
I am also including the TCTMD interview: